BOND-003 Cohort P Examines Gene Therapy for Papillary-Only BCG-Unresponsive #BladderCancer.
BOND-003 Cohort P in papillary-only BCG-unresponsive #NMIBC: @VikramNarayan @EmoryUniversity, joins @UroDocAsh @UTMDAnderson, to review topline cretostimogene data. In 56 patients, % at 9 months with no progression to MIBC. #WatchNow > bit.ly/4s9rBAo

Surgical Management of #NMIBC: Comparing En Bloc to Standard Resection Techniques.
En bloc vs conventional TURBT in #NMIBC: @jteoh_hk @CUHKMedicine, joins @UroDocAsh @UTMDAnderson to discuss optimizing resection. In EB-StaR, 1-year recurrence was 28.5% vs 38.1%; he recommends en ors <3 cm. #WatchNow > bit.ly/4yxXBQm

Postoperative Infection Rates: Single-Use vs Reusable Ureteroscopes.
Single-use vs reusable ureteroscopes: @BechisUrology @UCSD_Urology, joins @UroCancerMD @VUMChealth, to compare postoperative infection rates with each scope type and what the data mean for #Endourology practice. o/hyx7d8ogh9

Applications are now open for the 2026 PCF Leadership Academy.
This highly participatory, three-day program is designed for early- and mid-career U.S. urologists and medical oncologists entering or working in community-based practice. Participants will receive training in ip, multidisciplinary collaboration, and patient communication while building relationships with peers and expert mentors.
📍Santa Monica, California
📅 December 3–5, 2026
⏰ Applications will be accepted on a rolling basis until all available spots are filled. Please apply early to guarantee that your application will be reviewed.
✈️ Participants receive a stipend to support travel costs.
Apply now: bit.ly/4h7ilIe
Program details: bit.ly/4iFZuq7
#ProstateCancer #Urology #MedicalOncology #LeadershipDevelopment #ProstateCancerCare @PCFnews

Comparison of Mirabegron, Vibegron, and Anticholinergics for Incident #Dementia in #OveractiveBladder Treatment.
Do #OAB drugs raise dementia risk? @HijazAdonis, and David Sheyn, MD, join Alan Wein, MD, PhD(hon), FACS, @dsui_miami_uro to review two database studies. Dementia ith beta-3 agonists (~20%) and anticholinergics (~18-19%). #WatchNow on UroToday > bit.ly/4i1mjSY

Assessing Micturition, Sexual Function, and Endoscopic Outcomes One Year After Aquablation: A Single-Center Prospective Study.
One year after Aquablation, Qmax rose 103%, and IPSS fell 86%, with ejaculation preserved in 96.3% of men in a 109-patient prospective study. #BPH @danieleamparore > bit.ly/47TplnE @PorpigliaF @wjurol

Decipher® reclassification of NCCN risk groups in early #ProstateCancer. @danielkeizman joins @zklaassen_md to discuss a Decipher® transcriptomic analysis in a non-American prostate cancer cohort. The study found that Decipher® significantly reclassified a proportion of patients sk category in this population, where nearly all prior validation data came from American cohorts. #WatchNow on UroToday > bit.ly/3TCcjqA @Decipher_VCYT

ProTACT Trial Investigates Next-Generation PSMA-Targeted Alpha Therapy for #mCRPC.
Aaron Hansen, MBBS, FRACP joins @neerajaiims to discuss the Phase 1 ProTACT trial of 225Ac-FL-020. Among 15 heavily pretreated patients, no dose-limiting toxicities have been seen so far. #WatchNow dO

Genomic testing in metastatic APMR #ProstateCancer and its treatment implications. @DrRanaMcKay @UCSanDiego joins @neerajaiims @huntsmancancer to discuss genomic testing practices and recommends both germline and somatic NGS for all patients at this stage, preferring tissue over s utility when tissue is unavailable. #WatchNow to learn more > bit.ly/4gs8Cfh

Mast Cells and the Diagnosis of Interstitial Cystitis Bladder Pain Syndrome.
#InterstitialCystitis revisited: Stephen Walker, PhD @wakeurology joins Alan Wein, MD, PhD @dsui_miami_uro to discuss the role of mast cells in the diagnosis of IC/bladder pain syndrome and where the hNow > bit.ly/4in40Ij

CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized #ProstateCancer. Anna Wilkins, MD, PhD @ICR_London joins @AndreaMiyahira @PCFnews to discuss the @arteraAI MMAI score in 1,797 patients. It improved prediction beyond CPG and NCCN models. #WatchNow on UroToday > bit.ly/4i30C4S

SunRISe-4 Examines Neoadjuvant Cetrelimab and Gem-iDRS Prior to Cystectomy in Cisplatin-Ineligible Patients.
SunRISe-4 perioperative outcomes in cisplatin-ineligible #MIBC. @spsutkaMD @uwurology joins @UroCancerMD @VUMChealth to discuss neoadjuvant TAR-200 + cetrelimab: 85.2% in the protocol window, similar to cetrelimab alone. #WatchNow > bit.ly/3WtNgHK

TRITON-3 safety analysis of rucaparib in post-ARPI #mCRPC. @AlanBryce9 @cityofhope joins @PBarataMD @caseccc to discuss TRITON-3 safety data, focusing on rucaparib tolerability in BRCA/ATM-mutated mCRPC patients progressing after an ARPI. #WatchNow &gt; bit.ly/4pi2r1m

NIAGARA Trial Explores Urinary Tumor DNA as a Biomarker in Bladder Cancer.
Urinary tumor DNA in #MIBC from NIAGARA. @MichvdHeijden @NKI_nl joins @ERPlimackMD @FoxChaseCancer to discuss utDNA and ctDNA with perioperative durvalumab. pCR was 72% if utDNA-negative vs 18% if UroToday > bit.ly/4eCoewi

Prostate Cancer Working Group 4 Addresses PSMA PET as a Clinical Trial Endpoint.
PCWG4 brings PSMA PET into #ProstateCancer trial endpoints. Michael Morris, MD @MSKCancerCenter joins @sartor_oliver @EJHospital to discuss the new recommendations: 6+ new lesions on PSMA PET or bone on without a confirmatory scan. #WatchNow > bit.ly/4ytlhoR

Neoadjuvant Strategies in High-Risk Localized #ProstateCancer.
@dr_coops @UCSFCancer & @tranpt21 @UTMDAnderson join @PhillipKooMD @PCFnews to discuss emerging evidence from PROTEUS, #Decipher biomarker data from RTOG 0815, and CAN-2409, exploring opportunities to personalize treapare select patients ADT. #WatchNow on UroToday > bit.ly/4yXJmEM @Decipher_VCYT

Integrating clinical and genomic risk to guide abiraterone use in high-risk #ProstateCancer. Krishnan Patel, MD, MHS @UTMDAnderson sits down with @zklaassen_md @GACancerCenter presenting a pooled analysis of RTOG trials 9202, 9413, 9902, and 0521, examining whether the Decipher® oves risk stratification for abiraterone intensification decisions in high-risk localized prostate cancer. The study found that Decipher® improved prognostic discrimination over clinical factors alone for MFS, OS, and distant metastasis. #WatchNow on UroToday > bit.ly/4vuNjyO @Decipher_VCYT

New in @TheLancetOncol : outcomes for patients with #RCC brain metastases are changing.

In 1,049 patients, median OS was 20 months—up from 9.6–12 months in historical cohorts. Updated Renal GPA predicts survival from 4.8 to 51.2 months.

Important message: brain metastases y exclude patients from clinical trials.

Proud to contribute to this international effort led by Paul Sperduto and Minesh Mehta.

thelancet.com/journals/lanon…

@RifRahmanMD @SanjayAnejaMD @Luke_Pike_MD @TonyWangMD @SteveBraunstein @TugceKutukMD @Rrkotecha @DukeCancer @DukeRadOnc
@MiamiCancerInst @BaptistHealthSF

Real-World Data Explores Post-177Lu-PSMA-617 Therapies in Advanced #ProstateCancer.
What works after 177Lu-PSMA-617 in #mCRPC? @xiaoweimd joins @neerajaiims to discuss real-world PRECISION data in 442 patients: median PFS on the next therapy was 10.7 months with an ARPI and 7.2 WatchNow on UroToday > bit.ly/47YLAbM

Defining clinical complete response after neoadjuvant therapy in #MIBC. @TomFlaigMD @CUAnschutz and @CMercinelli @SanRaffaeleMI join @pjhensley11 @UKYMedicine at #IBCG2026; Dr. Flaig calls #IMvigor011 a turning point for ctDNA. #WatchNow on UroToday > bit.ly/3W6G4RI #IBCG26 @IBCG_BladderCA